Vanderbilt University's deal with Janssen Pharmaceutica NV is initially worth $10 million in funding for the lab run by Jeffrey Conn (at left), director of VU's drug-discovery program. The target: schizophrenia. VU stands to earn more than the base by meeting or surpassing milestones and through royalties on product sales. Janssen is based in Beerse, in the Antwerp province of Belgium, with U.S. offices in Titusville, N.J.Saturday, January 10, 2009
VU drug discovery, industry partnership
Vanderbilt University's deal with Janssen Pharmaceutica NV is initially worth $10 million in funding for the lab run by Jeffrey Conn (at left), director of VU's drug-discovery program. The target: schizophrenia. VU stands to earn more than the base by meeting or surpassing milestones and through royalties on product sales. Janssen is based in Beerse, in the Antwerp province of Belgium, with U.S. offices in Titusville, N.J.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment